CStone Pharma of Suzhou will test its PD-L1 monoclonal antibody in combination with Bayer Healthcare’s Stivarga® (regorafenib) as a treatment for multiple cancers including gastric cancer. Stivarga is a multi-kinase inhibitor that targets VEGFR, FGFR, CSF1R, etc. The two companies described the collaboration as a global effort with a China emphasis. CStone will be the study sponsor and Bayer will provide regorafenib throughout the clinical trial program.
Source: China Biotoday